Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis.

Mosche PompschNeslinur FisenkciPeter A HornMarkus KraemerMonika Lindemann

Published in: Neurological research and practice (2021)

T-cell-mediated response to Comirnaty® vaccination is observable despite attenuated humoral response in B-cell-depleted patients. This might enable partial protection against COVID-19. Trial registration Retrospectively registered.

Keyphrases

sars cov
immune response
end stage renal disease
newly diagnosed
coronavirus disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
study protocol
randomized controlled trial
toll like receptor
patient reported outcomes
phase ii
patient reported